T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
Radiant Logistics
RLGT
$400M
| $55K | ﹤0.01% |
+10,046
| New | +$59.6K |
|
2852
Willamette Valley Vineyards
WVVI
$11.5M
| $55K | ﹤0.01% |
10,850
| – | – |
|
2853
X4 Pharmaceuticals
XFOR
$425M
| $55K | ﹤0.01% |
1,310
+417
| +47% | +$11.6K |
|
2854
Harvard Bioscience
HBIO
$28.1M
| $54K | ﹤0.01% |
+1,262
| New | +$56.7K |
|
2855
Ovid Therapeutics
OVID
$489M
| $54K | ﹤0.01% |
17,396
+3,145
| +22% | +$10.5K |
|
|
WOW
2856
DELISTED
WideOpenWest
WOW
| $53K | ﹤0.01% |
14,616
+2,732
| +23% | +$9.76K |
|
|
PHLT
2857
DELISTED
Performant Healthcare Inc
PHLT
| $53K | ﹤0.01% |
18,015
+452
| +3% | +$1.29K |
|
2858
CEL-SCI Corp
CVM
$25.9M
| $52K | ﹤0.01% |
893
| – | – |
|
2859
Erasca
ERAS
$6.5B
| $51K | ﹤0.01% |
24,684
+4,753
| +24% | +$9.5K |
|
2860
Nerdy
NRDY
$93.7M
| $51K | ﹤0.01% |
17,248
+2,923
| +20% | +$9.01K |
|
|
PPTA
2861
Perpetua Resources
PPTA
$3.16B
| $51K | ﹤0.01% |
+12,049
| New | +$39.7K |
|
2862
Rafael Holdings
RFL
$103M
| $51K | ﹤0.01% |
29,731
| – | – |
|
2863
Humacyte
HUMA
$179M
| $50K | ﹤0.01% |
15,853
+405
| +3% | +$1.36K |
|
2864
BARK
BARK
$96.3M
| $49K | ﹤0.01% |
1,961
+422
| +27% | +$9.25K |
|
|
SAVAW
2865
DELISTED
Cassava Sciences, Inc. Warrant
SAVAW
| $49K | ﹤0.01% |
+11,944
| New | +$71.3K |
|
2866
Compass Therapeutics
CMPX
$427M
| $48K | ﹤0.01% |
24,055
+700
| +3% | +$1.21K |
|
2867
Nautilus Biotechnolgy
NAUT
$114M
| $48K | ﹤0.01% |
16,078
+4,239
| +36% | +$12K |
|
2868
Ampco-Pittsburgh
AP
$190M
| $47K | ﹤0.01% |
21,600
| – | – |
|
2869
PEDEVCO
PED
$150M
| $47K | ﹤0.01% |
2,875
| – | – |
|
2870
Trevi Therapeutics
TRVI
$2.53B
| $47K | ﹤0.01% |
+13,561
| New | +$30.3K |
|
|
SRTA
2871
Strata Critical Medical Inc
SRTA
$533M
| $46K | ﹤0.01% |
15,821
+566
| +4% | +$1.75K |
|
2872
Eos Energy Enterprises
EOSE
$1.54B
| $46K | ﹤0.01% |
43,930
+18,735
| +74% | +$19K |
|
2873
BioAtla
BCAB
$5.61M
| $45K | ﹤0.01% |
+256
| New | +$31.8K |
|
2874
Design Therapeutics
DSGN
$917M
| $45K | ﹤0.01% |
+11,147
| New | +$29.8K |
|
2875
FTC Solar
FTCI
$38.8M
| $45K | ﹤0.01% |
8,165
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.